Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity

H5N1 avian influenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to traditional vaccine technologies. In particular, polyanhydride nanoparticles encapsulating subunit...

Full description

Bibliographic Details
Main Authors:	Ross, Kathleen A, Loyd, Hyelee, Wu, Wuwei, Huntimer, Lucas, Ahmed, Shaheen, Sambol, Anthony, Broderick, Scott, Flickinger, Zachary, Rajan, Krishna, Bronich, Tatiana, Mallapragada, Surya, Wannemuehler, Michael J, Carpenter, Susan, Narasimhan, Balaji
Format:	Online
Language:	English
Published:	Dove Medical Press 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284014/

id	pubmed-4284014
recordtype	oai_dc
spelling	pubmed-42840142015-01-06 Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity Ross, Kathleen A Loyd, Hyelee Wu, Wuwei Huntimer, Lucas Ahmed, Shaheen Sambol, Anthony Broderick, Scott Flickinger, Zachary Rajan, Krishna Bronich, Tatiana Mallapragada, Surya Wannemuehler, Michael J Carpenter, Susan Narasimhan, Balaji Original Research H5N1 avian influenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to traditional vaccine technologies. In particular, polyanhydride nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cell-mediated immunity and provide protection upon lethal challenge. In this work, a recombinant H5 hemagglutinin trimer (H53) was produced and encapsulated into polyanhydride nanoparticles. The studies performed indicated that the recombinant H53 antigen was a robust immunogen. Immunizing mice with H53 encapsulated into polyanhydride nanoparticles induced high neutralizing antibody titers and enhanced CD4+ T cell recall responses in mice. Finally, the H53-based polyanhydride nanovaccine induced protective immunity against a low-pathogenic H5N1 viral challenge. Informatics analyses indicated that mice receiving the nanovaccine formulations and subsequently challenged with virus were similar to naïve mice that were not challenged. The current studies provide a basis to further exploit the advantages of polyanhydride nanovaccines in pandemic scenarios. Dove Medical Press 2014-12-30 /pmc/articles/PMC4284014/ /pubmed/25565816 http://dx.doi.org/10.2147/IJN.S72264 Text en © 2015 Ross et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Ross, Kathleen A Loyd, Hyelee Wu, Wuwei Huntimer, Lucas Ahmed, Shaheen Sambol, Anthony Broderick, Scott Flickinger, Zachary Rajan, Krishna Bronich, Tatiana Mallapragada, Surya Wannemuehler, Michael J Carpenter, Susan Narasimhan, Balaji
spellingShingle	Ross, Kathleen A Loyd, Hyelee Wu, Wuwei Huntimer, Lucas Ahmed, Shaheen Sambol, Anthony Broderick, Scott Flickinger, Zachary Rajan, Krishna Bronich, Tatiana Mallapragada, Surya Wannemuehler, Michael J Carpenter, Susan Narasimhan, Balaji Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
author_facet	Ross, Kathleen A Loyd, Hyelee Wu, Wuwei Huntimer, Lucas Ahmed, Shaheen Sambol, Anthony Broderick, Scott Flickinger, Zachary Rajan, Krishna Bronich, Tatiana Mallapragada, Surya Wannemuehler, Michael J Carpenter, Susan Narasimhan, Balaji
author_sort	Ross, Kathleen A
title	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_short	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_full	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_fullStr	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_full_unstemmed	Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
title_sort	hemagglutinin-based polyanhydride nanovaccines against h5n1 influenza elicit protective virus neutralizing titers and cell-mediated immunity
description	H5N1 avian influenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to traditional vaccine technologies. In particular, polyanhydride nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cell-mediated immunity and provide protection upon lethal challenge. In this work, a recombinant H5 hemagglutinin trimer (H53) was produced and encapsulated into polyanhydride nanoparticles. The studies performed indicated that the recombinant H53 antigen was a robust immunogen. Immunizing mice with H53 encapsulated into polyanhydride nanoparticles induced high neutralizing antibody titers and enhanced CD4+ T cell recall responses in mice. Finally, the H53-based polyanhydride nanovaccine induced protective immunity against a low-pathogenic H5N1 viral challenge. Informatics analyses indicated that mice receiving the nanovaccine formulations and subsequently challenged with virus were similar to naïve mice that were not challenged. The current studies provide a basis to further exploit the advantages of polyanhydride nanovaccines in pandemic scenarios.
publisher	Dove Medical Press
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284014/
_version_	1613173289365012480

Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity

Similar Items